Clinical Trial Update: Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update on intravitreal aflibercept (Eylea) for neovascular polypoidal choroidal vasculopathy (RIVAL trial).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polypoidal Choroidal Vasculopathy

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

Sponsor: Southeast Retina Center, Georgia | Conditions: Neovascular Polypoidal Choroidal Vasculopathy | Phase 4 | Status: UNKNOWN